In fairness, if there's someone who knows about investing in a cash-incinerator, it is you (and col, gavvy, baz, barman).
From FY21-23, your company burnt just a smidge under $230M USD on 'operations' (note, this doesn't even include paying interest costs or rent). How many patients did you recruit during that time? Does generating assay data really cost that much? Cynata seemed to produce the relevant potency data for less that 1% of the cost.
Good luck to you, champ
Ann: First Patient Treated in Phase 2 GvHD Trial, page-9
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
27.5¢ |
Change
-0.015(5.17%) |
Mkt cap ! $49.39M | |||
| Open | High | Low | Value | Volume |
| 29.0¢ | 29.0¢ | 26.0¢ | $30.21K | 109.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 63362 | 26.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 28.0¢ | 33487 | 1 |
View Market Depth
| Last trade - 15.51pm 21/05/2024 (20 minute delay) ? |
|
|||||
|
Last
27.5¢ |
Change
-0.015 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 29.0¢ | 29.0¢ | 26.5¢ | 46774 | ||
| Last updated 15.51pm 21/05/2024 ? | |||||
| CYP (ASX) Chart |